FDA Approves AstraZeneca's Etcamah Combo for 1st-Line HR+ Breast Cancer
AZN is trading near its 52-week low of $146.1 (11% above the low).
Summary
FDA approved AstraZeneca's Etcamah plus a CDK4/6 inhibitor for 1st-line HR+ breast cancer with emergent ESR1 mutations, backed by a 56% reduction in disease progression risk from the SERENA-6 trial.
Key Events · Product Development and Regulatory · AZN
-
FDA Approves Etcamah Combo
Etcamah (camizestrant) plus a CDK4/6 inhibitor approved for 1st-line advanced HR-positive, HER2-negative breast cancer with emergent ESR1 mutation — first and only medicine of its type in this setting.
-
SERENA-6 Efficacy Data
56% reduction in risk of disease progression or death (HR 0.44; median PFS 16.0 vs 9.2 months); PFS2 25.7 vs 19.1 months (HR 0.63); OS immature but trending favorably (HR 0.87).
-
Companion Diagnostic Approved
FDA concurrently approved a ctDNA-based companion diagnostic to detect emerging ESR1 mutations, enabling earlier therapy switching before disease progression.
-
Tenth FDA Approval in 2026
This is AstraZeneca's tenth FDA approval this year and fourth in breast cancer alone, underscoring oncology portfolio momentum.
Analysis · AZN · Life Sciences
AstraZeneca's Etcamah (camizestrant) plus a CDK4/6 inhibitor won US accelerated approval for 1st-line advanced HR-positive, HER2-negative breast cancer with emergent ESR1 mutations. The SERENA-6 trial showed a 56% reduction in risk of disease progression or death (HR 0.44; median PFS 16.0 vs 9.2 months), and a later analysis showed PFS2 of 25.7 vs 19.1 months. This is the first and only medicine of its type in the 1st-line setting, targeting roughly 30% of patients who develop ESR1 mutations before disease progression. The FDA also approved a companion ctDNA diagnostic, enabling earlier treatment switching. This is AstraZeneca's tenth FDA approval in 2026 and fourth in breast cancer alone, reinforcing its oncology franchise momentum.
How filings like this one have moved
In the 30 days to Sep 8, 2026, 45.2% of the 628 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AZN was trading at $161.61 on NYSE in the Life Sciences sector, with a market capitalization of approximately $252.3B. The 52-week trading range was $146.10 to $212.71. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.